Galectin-3 and the development of heart failure after acute coronary syndrome: Pilot experience from PROVE IT-TIMI 22

Clinical Chemistry

Volumn 58, Issue 1, 2012, Pages 267-273

  Grandin, E Wilson ^a   Jarolim, Petr ^a   Murphy, Sabina A ^a   Ritterova, Lea ^a   Cannon, Christopher P ^a   Braunwald, Eugene ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GALECTIN 3; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PILOT STUDY; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GALECTIN 3; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PILOT PROJECTS; PRAVASTATIN; PROGNOSIS; PROSPECTIVE STUDIES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84856072702     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.174359     Document Type: Article

References (25)

1. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8. (Pubitemid 39492008)
2. Kamal AK, Watanabe K, Ma M, Abe Y, ElBarbary R, Kodama M, Aizawa Y. A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy. Heart Vessels 2011;26:81-90.
3. Psarras S, Mavroidis M, Sanoudou D, Davos CH, Xanthou G, Varela AE, et al. Regulation of adverse remodelling by osteopontin in a genetic heart failure model. Eur Heart J [E-pub ahead of print 2011 Jul 20].
4. Liu Y-H, D'Ambrosio M, Liao T-D, Peng H, Rhaleb NE, Sharma U, et al. N-acetyl-seryl-aspartyl-lysylproline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296:H404-12.
5. van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24. (Pubitemid 44345127)
6. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, and Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12:826-32.
7. Lok DJA, van Der Meer P, de la Porte PWB-A, Lipsic E, Wijngaarden JV, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel biomarker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-8.
8. de Boer RA, Lok DJA, Jaarsma T, van Der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-8.
9. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385-90.
10. Felker GM, Fiuzat M, Shaw LK, Donahue M, Adams KF, Zannad F, et al. Prognostic value of galectin-3 in chronic heart failure: results from the HF-ACTION study. Eur Heart J 2010;31(Suppl 1):429.
11. Ueland T, Aukrust P, Broch K, Aakhus S, Skardal R, Muntendam P, Gullestad L. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 2011;150:361-4.
12. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold MO, Warnica JW, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE Study. J Am Coll Cardiol 2003;42:1446-53. (Pubitemid 37267288)
13. Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, and Levy D. Temporal trends in event rates after q-wave myocardial infarction: the Framingham Heart Study. Circulation 1999;100:2054-9. (Pubitemid 29532055)
14. Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, et al. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J 1999;138:1133-9.
15. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Pubitemid 38477774)
16. Christenson RH, Duh S-H, Wu AH, Smith A, Abel G, deFilippi CR, et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010;43:683-90.
17. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009;230:160-71.
18. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009;409:96-9.
19. Sharma U, Rhaleb N-E, Pokharel S, Harding P, Rasoul S, Peng H, Carretero OA. Novel antiinflammatory mechanisms N-acetyl-asp-lys-pro in hypertension induced target organ damage. Am J Physiol Heart Circ Physiol 2008;294:H1226-32. (Pubitemid 351468718)
20. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-98. (Pubitemid 351282017)
21. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006;103:5060-5.
22. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999;81:519-26. (Pubitemid 29203046)
23. Wang L, Friess H, Zhu Z, Frigeri L, Zimmermann A, Korc M, et al. Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 2000;80:1233-41. (Pubitemid 30637063)
24. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, et al. Role of galectin-3 in human pulmonary fibrosis. Allergol Int 2007;56:57-65. (Pubitemid 46449664)
25. Kasper M, Hughes RC. Immunocytochemical evidence for modulation of galectin-3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol 1996;179:309-16. (Pubitemid 26266411)